🎊Congrats to Lewis Nasr and M Zoghbi on this study of the MD Anderson Cancer Center real world experience with #immunotherapy in #UPS #sarcoma !
Data consistent with published litterature but need more collaboration for bigger histology-specific real world data!
mdpi.com/2072-6694/16/9…

📢 Out in ACS Journal Cancer
💊 #Dasatinib + #VEN in #CML -CP
👫N=65
🔹12-mo responses:
MMR=86%
MR4.5=45%
🔹4y EFS=96%,4y OS=100%
🔸Similar responses to Dasatinib monotherapy
🔸⬆️ rate of neutropenia
Full details below⏬ #leusm
OncoAlert
MD Anderson Cancer Center

acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Absolutely thrilled to have matched at BCM IM Residency !!

I’m grateful for mentors, friends, and family without whom none of it would have been possible.🍾

Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML : CR/CRi 96% and 18-month OS 72%. A new standard of care in this population.
Nicholas Short MD of MD Anderson Cancer Center #Leukemia
ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology
#leusm

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at Journal of Clinical Oncology
In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven)
Could be delivered safely with appropriate dose modifications.
ascopubs.org/doi/10.1200/JC…

Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated R/R #ALL . Study now amended to add navitoclax (BCL-xL inhibitor).
doi.org/10.1182/blooda…
@ASH_Hematology Blood Advances MD Anderson Cancer Center
#leusm

🚨Out in Blood Advances
💊Ph 1/2 VEN+low-intensity chemo from MD Anderson Cancer Center led by Nicholas Short MD
👫 22 pts w/ #ALL
🔹CR/CRi 57%, MRD neg 45%, 4 SCT
🔹DOR 6.3 mo, OS 7.1 mo, 1y OS 29%
🔸AEs=infection, FN
➡️ Active combo in R/R ALL
#leusm OncoAlert

ashpublications.org/bloodadvances/…

🚨Very promising results with 'dose-dense' miniHCVD+Blina+InO
👫N=21 (ND, MRD+, R/R)
🔹ND ➡️ 100% CR/CRi & MRD- ➡️ 1y OS 83%
🔹R/R ➡️ 63% CR/CRi
🔹No new sfaety signals
✅ Prospective trials evaluating this combo at MD Anderson Cancer Center
#OncoAlert #leusm

clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

It was a true pleasure! Thank you for having me on the podcast.

🚨 IM #programs Full support for Lewis Nasr working as post-doc at MD Anderson Cancer Center Nicholas Short MD Hagop Kantarjian,MD
✅ Extremely hardworking
✅ Super motivated
✅ Great character
✅ Team player
✅ Highly reliable and trustworthy

💯 Recommended for #TOP programs!!
#MedTwitter

Hello #MedTwitter !

I'm Lewis Nasr, USJ alumnus🇱🇧 currently doing research at MD Anderson Cancer Center.

I'm thrilled to be applying to #InternalMedicine residency this #Match2024 .

Wishing all applicants the best of luck, I look forward to connect!

'I liken Dr. Kantarjian to a conductor of a symphony. And he can tweak it as he's conducting and the patients derive the benefit,' says survivor Bev Lewyn. Watch to learn more about Dr. Kantarjian, recipient of the David A. Karnofsky Memorial Award from ASCO. #ASCO23 #EndCancer

🔥Just in🔥

👉🏻 Could #AI -based online chat potentially become a validated tool for assisting in patient #education ?

👉🏻 86% of #ChatGPT answered questions on various #oncology topics were accurate according to #oncologists .

Frontiers - Oncology OncoAlert

frontiersin.org/articles/10.33…

👉🏻Emerging #liquidbiopsy tech is reshaping #MRD detection in #lymphoidmalignancies , offering a less invasive alternative to bone marrow aspirations.

👉🏻 #AI integration is promising to streamline this highly technical process.

frontiersin.org/articles/10.33…

Read how Dr. Garth Graham, head of YouTube's health efforts, & Shiv Gaglani are helping raise awareness for rare diseases through the power of video… blog.youtube/news-and-event…

What a day! It was great to be back in person for MD Anderson's Boot Walk to End Cancer. Thanks to the more than 5,100 people who participated here in Houston and around the world. #EndCancer

Early evidence from China suggested that blood groups may be involved in COVID-19 susceptibility/severity, but several subsequent studies reported controversial results. Check out our latest case-control study on the topic at Hôtel-Dieu de France with Pr Moussa Riachy
pubmed.ncbi.nlm.nih.gov/34755349/

First-Line Treatment Outcomes of CML Patients in a Real-World Data Setting in Lebanon epostersonline.com/soho2021/node/… #soho2021

To outperform, you need serious competitive advantages.

But contrary to what you have been told, most of them don't require talent.

10 competitive advantages that you can start developing today:

231 million doses of vaccine and no deaths from it. 118 million COVID cases and 2,620,000 deaths. It's really your call which one you want to do. But you should at least have the facts before you make the decision.